Welcome to our dedicated page for Biodexa Pharmaceuticals Plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals PLC is conducting a primary offering of 82,809 American Depositary Shares, each representing 500,000 ordinary shares, at a price of $2.85 per Depositary Share and is issuing 200,143 pre-funded warrants in lieu of certain Depositary Shares.
The prospectus supplement describes a concurrent private placement of Series M warrants exercisable for 282,952 Depositary Shares, related warrant inducement and a second private placement, and states expected gross offering proceeds, placement agent fees and estimated net proceeds to the company.
Biodexa Pharmaceuticals PLC reported the results of its rescheduled Annual General Meeting held on June 30, 2026. Ordinary resolutions 1 through 7 were approved, with voting majorities of 94%, 73%, 92%, 81%, 81%, 91% and 94%, showing broad support for core business items.
Ordinary resolution 8 and special resolution 10 did not pass, and resolution 11 also failed because it was contingent on resolution 8. The company remains a clinical stage biopharmaceutical developer focused on gastrointestinal cancers and other diseases with unmet medical needs through programs such as eRapa, MTX240 and tolimidone.
Biodexa Pharmaceuticals PLC has priced a group of equity and warrant transactions expected to raise approximately $3.5 million in gross proceeds through a registered offering, a concurrent private placement and a warrant exercise inducement.
The deals combine sales of American depositary shares and pre-funded warrants at $2.85 per ADS (or $2.8499 per pre-funded warrant) with new Series M, N and O warrants that, once shareholder approval is obtained, will allow the investor to purchase additional ADSs over five years at the same exercise price. Certain existing Series L warrants will be exercised for cash at the reduced price of $2.85 in exchange for issuing Series O warrants at a 200% ratio to ADSs received.
The company has engaged Maxim Group LLC as exclusive placement and inducement agent, agreeing to pay an 8.0% cash fee on gross proceeds plus expenses, and has entered into a registration rights agreement to register resales of the warrants and the ADSs issuable upon their exercise.
Biodexa Pharmaceuticals PLC reports that its Annual General Meeting scheduled for June 17, 2026 was adjourned due to lack of a quorum. In line with its articles of association, the meeting has been re-scheduled for 11:00 a.m. London time on June 30, 2026 at the company’s Cardiff registered office.
Proxies submitted in time for the original AGM will remain valid for the new date. The company is a clinical stage biopharmaceutical business with lead programs eRapa, MTX240 and tolimidone targeting gastrointestinal cancers, Familial Adenomatous Polyposis, Non-Muscle Invasive Bladder Cancer, GIST and type 1 diabetes.
Biodexa Pharmaceuticals Plc filed an amendment to a Schedule 13G/A reporting that Armistice Capital, LLC and Steven Boyd jointly beneficially own 187,975 American Depositary Shares, representing 9.99% of the class. Each ADS represents four hundred ordinary shares. The filing states Armistice Capital exercises shared voting and dispositive power over the reported shares on behalf of its client, Armistice Capital Master Fund Ltd., and that the Master Fund "disclaims beneficial ownership" of the shares by virtue of its Investment Management Agreement. The filing is signed by Steven Boyd on 05/15/2026.
Biodexa Pharmaceuticals PLC has called its Annual General Meeting for 17 June 2026 and is asking shareholders to approve a major share capital reorganisation. On 6 May 2026 the company had 373,056,808,922 existing ordinary shares, equal to about 746,113 ADSs at a 500,000:1 ratio.
The Board proposes consolidating every 10,000 existing ordinary shares into one £0.01 consolidated share, then subdividing each into one new ordinary share of £0.000001 and 9,999 E deferred shares with negligible rights. The ADS ratio would change to 50 ordinary shares per ADS so the number of ADSs remains about 746,113.
Shareholders are also being asked to grant authority to allot new shares up to £25,000,000 nominal and to disapply pre-emption rights on the same amount until the 2029 AGM, and to adopt new articles of association to accommodate the new E deferred shares.
Biodexa Pharmaceuticals PLC is registering the issuance of up to 489,000 American Depositary Shares (each ADS = 100,000 Ordinary Shares) representing 48,900,000,000 Ordinary Shares issuable upon exercise of Pre-Funded Warrants, plus up to 6,097,562 ADS representing 609,756,200,000 Ordinary Shares issuable upon exercise of Series L Warrants, and up to 152,439 ADS representing 15,243,900,000 Ordinary Shares issuable upon exercise of Placement Agent Warrants.
The prospectus describes exercise prices (Pre-Funded Warrants at $0.0001 per Depositary Share; Series L and Placement Agent Warrants at $3.28 per Depositary Share), cash‑or‑cashless exercise mechanics, beneficial ownership limits (commonly 9.99% or 4.99%) and plan of distribution terms. It also states 324,156,808,922 Ordinary Shares outstanding as of March 12, 2026 and a pro forma total of 998,056,908,922 Ordinary Shares assuming full exercise of the referenced warrants.
Biodexa Pharmaceuticals PLC registered for resale an aggregate of 943,400,000 Ordinary Shares represented by 9,434 Depositary Shares, issuable upon exercise of Series G warrants. The prospectus states the company will not receive any proceeds from resale by the selling shareholders; net proceeds will go to those selling shareholders, although the company would receive proceeds if warrants are exercised for cash. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.
Biodexa Pharmaceuticals PLC registers for resale 1,701,800,000 Ordinary Shares represented by 17,018 Depositary Shares, each Depositary Share representing 100,000 Ordinary Shares, for sale from time to time by identified selling shareholders.
The prospectus states the Company will receive no proceeds from resale by the selling shareholders, although the Company may receive proceeds if Series J warrants are exercised for cash; if all Series J warrants were exercised for cash in full, proceeds would be approximately $4.3 million. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 1, 2026.